RE:2020 outlook review correct. They used the term anticipate without the caveat that this was dependent on funding that was clearly not locked in at this point. This is why many of us have been losing patience, except for a few longs who are apparently close to the company and have more trust.
I think ProMIS will do well going forward. I do think that the last few years were more uncertain than they communicated, but the Boston investors and the Biogen approval changed the trajectory for us. I just wish I could have been focusing my money elsewhere during that phase of uncertainty. Now though, I think we are getting closer to those long awaited announcements of funding and/or partnership sufficient for execution of PhI of PMN310. I think market cap will exceed that of accumen at that point.
just my opinions.. good luck.